Lantheus Holdings
Lantheus Holdings Inc is an American radiopharmaceutical company developing and commercializing diagnostic imaging agents and targeted therapeutics. The company provides diagnostic products including Pylarify for prostate cancer imaging, Definity ultrasound contrast agents, and TechneLite radiopharmaceutical generators. Revenue is generated from the sale of radiopharmaceutical diagnostic agents, targeted therapeutics, and specialized radioisotopes to healthcare facilities. Core end markets serve nuclear medicine departments, hospital radiology centers, oncology practices, and cardiology clinics across North America and international markets. Lantheus Holdings holds a market-leading position in nuclear medicine and radiopharmaceutical diagnostic agents in the United States. The company is headquartered in Bedford, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.
10 of the funds FundTelligence covers report a position in Lantheus Holdings.
- Legal name
- Lantheus Holdings Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 10
Funds holding Lantheus Holdings
- Lannebo Global Småbolag — Lannebo · 1.8 % (full portfolio disclosed, June 2026)
- JPM US Small Cap Growth Fund — JPM · 0.89 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.64 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.49 % (full portfolio disclosed, June 2026)
- Schroder ISF Global Convertible Bond — Schroders · 0.28 % (full portfolio disclosed, June 2026)
- Nordea BetaPlus Enhanced Global Sustainable Small Cap — Nordea Funds · 0.15 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.07 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.07 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 10 funds holding it.